Study Indicates Scleroderma Mortality Rates Being Underestimated PDF Print E-mail
Saturday, 25 May 2013 09:09
Scleroderma patients have a significantly reduced life expectancy that is most likely being underestimated, delegates have heard. Most studies on scleroderma survival are based on prevalent cohorts, where no limit is placed on disease duration at the time of recruitment. This leaves results wide open to “survival bias”.

In a bid to overcome the issue and get to the true figures, Dr Nikpour and colleagues from across Australia evaluated the survival rates of nearly 1,300 scleroderma patients from 13 centres, compared with the general Australian population. Patients were studied as an entire cohort, but also as a separate cohort of patients who had been recruited within 5 years of disease onset.

The figures told a different story. In the whole cohort, there were 27 deaths (15 diffuse and 12 limited disease) over the 8 year study period. Twenty five of these 27 deaths were in the subset of patients with early disease. Ten year survival of patients with diffuse disease in the overall cohort was 90% whereas in the early disease cohort it was 70% -- clear evidence that survival bias was alive and kicking, Dr Nikpour said.

Fifteen of the deaths in the first decade were scleroderma-related and all were caused by either heart or lung manifestations. The remaining 12 deaths were not deemed to be  scleroderma related and most were malignancies.

Overall, the study found that the standard mortality ratios were 8.8 for men and 6.4 for women - figures higher than previously reported, Dr Nikpour said.

“Scleroderma carries substantial mortality. The average standard mortality rate of 6.8 in our Australian patients is one of the highest reported and is comparable to some types of malignancies” Dr Nikpour said. The SMR reported here is considerably higher than the SMR of 1.5 recorded in the South Australian registry, she said.

But there may be a variety of explanations for the discrepancy.  There could be differences in scleroderma case definition, death case ascertainment and survival bias, she said. Nevertheless the results were a “compelling rationale” for establishing a large multinational inception cohort of patients with scleroderma to follow disease outcomes, she concluded.

Source: Rheumatology Update (2013)

 
More articles :

» Vascular Changes in Bleomycin-Induced Scleroderma

Toshiyuki Yamamoto and Ichiro KatayamaDepartment of Dermatology, Fukushima Medical University, Hikarigaoka 1, Fukushima 960-1295, JapanDepartment of Dermatology, Osaka University, Yamadaoka 2-2, Suita, Osaka 565-0871, JapanReceived 6 June 2011;...

» Stanford Medical Researchers Discover Master Regulator of Skin Development

The surface of your skin, called the , is a complex mixture of many different cell types — each with a very specific job. The production, or differentiation, of such a sophisticated tissue requires an immense amount of coordination at the cellular...

» 7 Tips For Maintaining Healthier Skin In Scleroderma

Scleroderma is a rare, connective tissue disease in which the body’s normal tissue is replaced with thick, dense tissue, due to the overproduction of collagen. Although can affect other parts of the body including the kidneys, hearts, and...

» A Guide to Managing Your Child’s Scleroderma

Although localized and systemic sclerodermas are very different diseases, living with a child who has either disease represents a special set of problems. Indeed the issues faced by the parents of children with most chronic diseases are the same....

» Blocking TGFβ via Inhibition of the αvβ6 Integrin: A Possible Therapy for Systemic Sclerosis Interstitial Lung Disease

Tamiko R. Katsumoto, Shelia M. Violette, and Dean SheppardReceived 27 May 2011; Accepted 15 August 2011Interstitial lung disease (ILD) is a commonly encountered complication of systemic sclerosis (SSc) and accounts for a significant proportion of...

» Active Biotech Presents Data regarding the 57-57 Project at EULAR

Active Biotech (NASDAQ OMX Nordic: ACTI) has presented data from an exploratory clinical trial in Systemic Lupus Erythematosus (SLE) patients at the Annual European Congress of Rheumatology EULAR 2011, an international event for specialists in the...